Kosaka, Takeo

写真a

Affiliation

School of Medicine, Department of Urology (Shinanomachi)

Position

Assistant Professor/Senior Assistant Professor
Page Top ▲

Career 【 Display / hide 】

  • 2000
    -
    2002.06

    防衛医科大学校病院・自衛隊中央病院・初任実務研修医

  • 2002.06
    -
    2004.07

    陸上自衛隊　第１２後方支援衛生隊　

  • 2002.06
    -
    2004.07

    防衛医科大学校　泌尿器科　通修医

  • 2002.06
    -
    2004.07

    村山医療センター　泌尿器科　通修医, 非常勤研究医

  • 2004.08
    -
    2006.07

    防衛医科大学校　泌尿器科　専門研修医

display all >>

Page Top ▲

Academic Background 【 Display / hide 】

  • 2008.04
    -
    2012.03

    Keio University, 大学院医学研究科, 外科系泌尿器

    Graduate School, Completed

  • 1994.04
    -
    2000.03

    National Defense Medical College, 医学部, 医学科

    University, Graduated

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 医学博士, Keio University, Coursework, 2012

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 日本がん治療学会　暫定教育医

  • 医師免許, 2000.05

  • 日本泌尿器科学会　専門医, 2005

  • 日本泌尿器科学会　指導医, 2010

  • 日本がん治療学会　認定医, 2011.04

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Urology

Page Top ▲

Research Keywords 【 Display / hide 】

  • Liquid biopsy

  • Prostate cancer

  • Castration Resistant Prostate Cancer

  • Stem cell

  • Drug Resistance

Page Top ▲

Research Themes 【 Display / hide 】

  • Mechanic analysis of CRPC, 

    2000.06
    -
    Present

Page Top ▲
 

Papers 【 Display / hide 】

  • MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer

    Yasumizu Y., Rajabi H., Jin C., Hata T., Pitroda S., Long M.D., Hagiwara M., Li W., Hu Q., Liu S., Yamashita N., Fushimi A., Kui L., Samur M., Yamamoto M., Zhang Y., Zhang N., Hong D., Maeda T., Kosaka T., Wong K.K., Oya M., Kufe D.

    Nature Communications (Nature Communications)  11 ( 1 )  2020.12

    　View Summary

    © 2020, The Author(s). Neuroendocrine prostate cancer (NEPC) is an aggressive malignancy with no effective targeted therapies. The oncogenic MUC1-C protein is overexpressed in castration-resistant prostate cancer (CRPC) and NEPC, but its specific role is unknown. Here, we demonstrate that upregulation of MUC1-C in androgen-dependent PC cells suppresses androgen receptor (AR) axis signaling and induces the neural BRN2 transcription factor. MUC1-C activates a MYC→BRN2 pathway in association with induction of MYCN, EZH2 and NE differentiation markers (ASCL1, AURKA and SYP) linked to NEPC progression. Moreover, MUC1-C suppresses the p53 pathway, induces the Yamanaka pluripotency factors (OCT4, SOX2, KLF4 and MYC) and drives stemness. Targeting MUC1-C decreases PC self-renewal capacity and tumorigenicity, suggesting a potential therapeutic approach for CRPC and NEPC. In PC tissues, MUC1 expression associates with suppression of AR signaling and increases in BRN2 expression and NEPC score. These results highlight MUC1-C as a master effector of lineage plasticity driving progression to NEPC.

  • A Japanese patient with ductal carcinoma of the prostate carrying an adenomatosis polyposis coli gene mutation: a case report

    Umeda K., Kosaka T., Nakamura K., Takeda T., Mikami S., Nishihara H., Oya M.

    Diagnostic Pathology (Diagnostic Pathology)  15 ( 1 )  2020.08

    　View Summary

    © 2020 The Author(s). Background: Ductal carcinoma of the prostate is a histological subtype with a higher mortality than acinar adenocarcinoma. The number of cases is small and there are no treatment guidelines. We believe that this is the first report of ductal carcinoma of the prostate with an adenomatosis polyposis coli (APC) gene mutation in Japan. Case presentation: An 85-year-old man presented with gross hematuria, and a papillary tumor in the prostatic urethra that was diagnosed as ductal carcinoma of the prostate following transurethral resection. Genetic analysis found an APC mutation with loss of heterozygosity. Immunostaining revealed focal nuclear translocation of β-catenin. APC mutations associated with loss of β-catenin degradation in the Wnt signaling pathway and result in over accumulation of β-catenin are thought to increase mortality. In this patient, β-catenin migrated into tumor cell nuclei. Conclusion: To the best of our knowledge, this is the first report of ductal carcinoma of the prostate with an APC mutation in Japan. The development of a therapeutic Wnt inhibitor is discussed.

  • Type of patients in whom biochemical recurrence after radical prostatectomy can be observed without salvage therapy

    Matsumoto K., Niwa N., Hagiwara M., Kosaka T., Tanaka N., Takeda T., Morita S., Mizuno R., Shinojima T., Hara S., Asanuma H., Oya M.

    World Journal of Urology (World Journal of Urology)  38 ( 7 ) 1749 - 1756 2020.07

    ISSN  07244983

    　View Summary

    © 2019, Springer-Verlag GmbH Germany, part of Springer Nature. Purpose: To examine the prognosis after BCR with and without salvage therapy, including radiation and/or androgen deprivation. Methods: The study population consisted of 431 patients, all of whom underwent radical prostatectomy and developed BCR (PSA > 0.2 ng/mL). According to the two risk factors [Gleason score ≥ 8 and PSA-doubling time (DT) < 6 months], we divided the patients into two groups. The high/intermediate-risk group consisted of patients with both or one risk factor. On the other hand, patients with neither factor were in the low-risk group. We set the starting point at the timing of BCR, and the endpoints were development to castration-resistant prostate cancer (CRPC) and cancer-specific death. Results: During the mean follow-up period of 8.3 years after BCR, CRPC was observed in 49 patients (11.4%), and 21 patients (4.9%) died due to prostate cancer. We first divided the 191 high/intermediate-risk patients according to the PSA level (PSA < 1.0 ng/mL, PSA 1.0–4.0, and PSA > 4.0 or no therapy) at the initiation of salvage therapy, including radiation and/or androgen deprivation. We found that delayed (PSA > 4.0 ng/mL) or no salvage therapy was significantly associated with CRPC and cancer-specific death. In the 240 low-risk patients, Kaplan–Meier curves demonstrated no significant difference in CRPC-free survival or cancer-specific survival within 10 years from the timing of BCR. Conclusions: Observation after BCR without salvage therapy or delayed administration may be an option for low-risk patients with a Gleason score ≤ 7 and PSA-DT ≥ 6 months when their life expectancy is within 10 years.

  • External validation of the "optimal PSA follow-up schedule after radical prostatectomy” in a new cohort

    Yanai Y., Matsumoto K., Kosaka T., Takeda T., Tanaka N., Morita S., Mizuno R., Shinojima T., Asanuma H., Oya M.

    International Journal of Clinical Oncology (International Journal of Clinical Oncology)  25 ( 7 ) 1393 - 1397 2020.07

    ISSN  13419625

    　View Summary

    © 2020, Japan Society of Clinical Oncology. Background: Biochemical recurrence (BCR) after radical prostatectomy (RP) is most commonly diagnosed by detecting an increase in asymptomatic prostate-specific antigen (PSA). We previously reported the “optimal PSA follow-up schedule after RP”. The aim of this study was to confirm the usefulness and safety of that follow-up schedule in another cohort. Methods: We retrospectively reviewed the clinicopathological data of 798 consecutive patients who underwent radical prostatectomy between 2009 and 2017. We examined all PSA values measured during follow-up. Furthermore, we estimated the PSA value when we observed the “optimal PSA follow-up schedule” at each timing in the virtual follow-up. BCR was defined as an elevation of PSA to greater than 0.2 ng/ml, and the ideal PSA range for detection of BCR was regarded to be 0.2–0.4 ng/ml. Results: During the mean follow-up period of 5.8 years, BCR occurred in 115 (14.9%) patients and the frequency of virtual follow-up was significantly lower than the actual frequency. However, overlooking of BCR (detecting BCR when PSA exceeded 0.4 ng/ml) was observed in 17 patients, which is higher than the actual frequency of overlooking (12 patients). Therefore, we modified the follow-up schedule, which could achieve the lower follow-up frequency and a limited number of overlooking of BCR (7 patients). Conclusion: This external validation study revealed that the "modified optimal PSA follow-up schedule after RP" can reduce the frequency of PSA measurement with a limited risk of overlooking BCR.

  • Appropriate timing for a biochemical evaluation after adrenalectomy for unilateral aldosterone-producing adenoma

    Takamatsu K., Takeda T., Hattori S., Tanaka N., Morita S., Matsumoto K., Kosaka T., Mizuno R., Shinojima T., Kikuchi E., Asanuma H., Kurihara I., Itoh H., Oya M.

    Clinical Endocrinology (Clinical Endocrinology)  92 ( 6 ) 503 - 508 2020.06

    ISSN  03000664

    　View Summary

    © 2020 John Wiley & Sons Ltd Context: The oversecretion of plasma aldosterone by unilateral aldosterone-producing adenoma (APA) can be cured by adrenalectomy. However, the time needed for the endocrine environment to normalize remains unclear. Objective: To clarify adequate timing for a biochemical evaluation in unilateral APA patients after adrenalectomy. Design and patients: A total of 166 unilateral APA patients were retrospectively reviewed. We evaluated the plasma aldosterone concentration (PAC) (pg/mL), active renin concentration (ARC) (pg/mL), aldosterone-renin ratio (ARR; PAC/ARC), serum potassium concentration and estimated glomerular filtration rate (eGFR) at 1, 3 and 6 postoperation months (POM). Results: PAC was significantly lower at 1POM than at presurgery (presurgery; 407.2, 1 POM; 90.0 pg/mL, P <.001). ARC did not increase from baseline at 1POM, but significantly increased at 3POM (presurgery; 4.43, 1POM; 4.87, 3POM; 11.3 pg/mL, P <.001). ARR significantly decreased at 1POM (presurgery; 146.9, 1 POM; 26.3, P <.001) although ARC did not increase at 1POM. Among the 34 patients who had hypokalaemia presurgery, it was resolved in 28 (82%) at 1POM and in all (100%) at 3POM. The biochemical outcomes at 1POM were 131 (79%) complete, 20 (12%) partial and 15 (9%) absent successes, while at 3POM, 147 (89%) were complete, 9 (5%) partial and 10 (6%) absent. Twenty-three (14%) patients were reclassified into different biochemical outcomes between 1 and 3POM, whereas only 5 (3%) changed between 3 and 6POM. Conclusion: The appropriate timing for a biochemical evaluation of unilateral APA patients treated with laparoscopic adrenalectomy appears to be 3 months or more after surgery.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

Page Top ▲

Presentations 【 Display / hide 】

  • PREDICTING PROSTATE SPECIFIC ANTIGEN RECURRENCE AFTER RADICAL PROSTATECTOMY BY CLINICOPATHOLOGICAL FACTORS: SUITABILITY OF MAGNETIC RESONANCE IMAGING

    Hattori, Seiya, Kosaka, Takeo, Mizuno, Ryuichi, Yasumizu, Yota, Miyajima, Akira, Nagata, Hirohiko, Yazawa, Satoshi, Kikuchi, Eiji, Nakagawa, Ken, Mikami, Shuji, Tanimoto, Akihiro, Jinzaki, Masahiro, Oya, Mototsugu

    JOURNAL OF UROLOGY, 

    2013.04
    , 

    Poster presentation

  • UNDETECTABLE TUMOR THROUGH PREOPERATIVE MRI PREDICTS ORGAN CONFINED DISEASE AND LOWER TUMOR VOLUME IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER

    Muro, Yusuke, Mizuno, Ryuichi, Yazawa, Satoshi, Kosaka, Takeo, Morita, Shinya, Kono, Hidaka, Kikuchi, Eiji, Asanuma, Hiroshi, Miyajima, Akira, Nakagawa, Ken, Jinzaki, Masahiro, Oya, Mototsugu

    JOURNAL OF UROLOGY, 

    2013.04
    , 

    Oral presentation (general)

  • THE DISTINCT ASSOCIATION BETWEEN PRIMARY TUMOR LOCATION AND THE PATTERNS OF METASTATIC SPREAD FOLLOWING RADICAL NEPHROURETERECTOMY IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA

    Tanaka, Nobuyuki, Kikuchi, Eiji, Kanao, Kent, Matsumoto, Kazuhiro, Kobayashi, Hiroaki, Ide, Hiroki, Miyazaki, Yasumasa, Obata, Jun, Hoshino, Katsura, Shirotake, Suguru, Kosaka, Takeo, Miyajima, Akira, Momma, Tetsuo, Nakajima, Yosuke, Hasegawa, Shintaro, Nakagawa, Ken, Jinzaki, Masahiro, Oya, Mototsugu

    JOURNAL OF UROLOGY, 

    2013.04
    , 

    Oral presentation (general)

  • Does Pelvic Lymph Node Dissection Improve the Biochemical Relapse-Free Survival in Low-Risk Prostate Cancer Patients Treated by Laparoscopic Radical Prostatectomy?

    Daimon, Tatsuaki, Miyajima, Akira, Maeda, Takahiro, Hattori, Seiya, Yasumizu, Yota, Hasegawa, Masanori, Kosaka, Takeo, Kikuchi, Eiji, Nakagawa, Ken, Oya, Mototsugu

    JOURNAL OF ENDOUROLOGY, 

    2012.09
    , 

    Oral presentation (general)

  • ELEVATED EXPRESSION OF ARYL HYDROCARBON RECEPTOR IN RENAL CELL CARCINOMA IS ASSOCIATED WITH CIGARETTE SMOKE AND THE PROGNOSIS

    Ishida, Masaru, Mikami, Shuji, Kosaka, Takeo, Kono, Hidaka, Kikuchi, Eiji, Nagata, Hirohiko, Miyajima, Akira, Nakagawa, Ken, Mukai, Makio, Okada, Yasunori, Oya, Mototsugu, Oya, Mototsugu

    JOURNAL OF UROLOGY, 

    2009.04

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • Elucidation of the molecular control mechanism of refractory prostate cancer that includes lineage plasticity and establishment of individualized treatment strategies

    2024.04
    -
    2028.03

    基盤研究(B), Principal investigator

  • Elucidation of tumor development mechanism by immune escape mechanism through metabolic reprogramming of anticancer drug-resistant cancer

    2023.06
    -
    2026.03

    挑戦的研究（萌芽）, Principal investigator

  • 神経内分泌前立腺がんのシングルセル解析による病態解明と新規治療戦略の確立

    2021.07
    -
    2023.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Challenging Research (Exploratory), Principal investigator

  • Integrated analysis of ITH in drug resistant prostate cancer by single cell analysis

    2020.04
    -
    2023.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Principal investigator

  • 前立腺癌における不均一性と可塑性を標的とした新規バイオマーカー探索と新規治療戦略

    2017.04
    -
    2020.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

display all >>

Page Top ▲

Intellectual Property Rights, etc. 【 Display / hide 】

  • 抗がん剤の効果増強薬

    Date applied： 2012-127405   

    Date issued： 5947623 

    Patent, Joint

Page Top ▲

Awards 【 Display / hide 】

  • AUA Annual Meeting Best of Posters

    2018

    Type of Award： International academic award (Japan or overseas)

  • 16th Urological Association of Asia Congress; Best Abstract Award

    2018

    Type of Award： International academic award (Japan or overseas)

  • 第16回関東ホルモンと癌研究会　研究奨励賞

    2016

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • #103 Japan Urological Association Annual Meeting

    2015, 日本泌尿器科学会

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 慶應義塾大学医学部 三四会奨励賞

    2014

    Type of Award： Keio commendation etc.

display all >>

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • LECTURE SERIES, UROLOGY

    2024

  • LECTURE SERIES, UROLOGY

    2023

  • LECTURE SERIES, UROLOGY

    2022

  • LECTURE SERIES, UROLOGY

    2021

  • LECTURE SERIES, UROLOGY

    2020

display all >>

Page Top ▲

Educational Activities and Special Notes 【 Display / hide 】

  • 第5回　HBOC教育セミナー　テキスト

    2018.10

    , Development of Textbook and Teaching Material

  • 第4回　HBOC教育セミナー　テキスト

    2018.05

    , Development of Textbook and Teaching Material

  • 第3回　HBOC教育セミナー　テキスト

    2018.02

    , Development of Textbook and Teaching Material

  • 第2回　HBOC教育セミナー　テキスト

    2017.06

    , Development of Textbook and Teaching Material

  • 第1回　HBOC教育セミナー　テキスト

    2017.02

    , Development of Textbook and Teaching Material

display all >>

Page Top ▲
 

Social Activities 【 Display / hide 】

  • PSAスクリーニングキャンペーン

    2012
    -
    Present
Page Top ▲

Committee Experiences 【 Display / hide 】

  • 2015.04
    -
    Present

    プログラム委員, 前立腺研究財団

Page Top ▲